Aims We investigated the role of src-family kinases (srcFKs) in hypoxic pulmonary vasoconstriction (HPV) and how this relates to Rho-kinase-mediated Ca 2þ sensitization and changes in intracellular Ca 2þ concentration ([Ca 2þ ] i ). Methods and results Intra-pulmonary arteries (IPAs) were obtained from male Wistar rats. HPV was induced in myograph-mounted IPAs. Auto-phosphorylation of srcFKs and phosphorylation of the regulatory subunit of myosin phosphatase (MYPT-1) and myosin light-chain (MLC 20 ) in response to hypoxia were determined by western blotting. Translocation of Rho-kinase and effects of siRNA knockdown of src and fyn were examined in cultured pulmonary artery smooth muscle cells (PASMCs). [Ca 2þ ] i was estimated in Fura-PE3-loaded IPA. HPV was inhibited by two blockers of srcFKs, SU6656 and PP2. Hypoxia enhanced phosphorylation of three srcFK proteins at 59, and 54 kDa, corresponding to src, fyn, and yes, respectively) and enhanced srcFK-dependent tyrosine phosphorylation of multiple target proteins. Hypoxia caused a complex, time-dependent enhancement of MYPT-1 and MLC 20 phosphorylation, both in the absence and presence of pre-constriction. The sustained component of this enhancement was blocked by SU6656 and the Rho-kinase inhibitor Y27632. In PASMCs, hypoxia caused translocation of Rho-kinase from the nucleus to the cytoplasm, and this was prevented by anti-src siRNA and to a lesser extent by anti-fyn siRNA. The biphasic increases in [Ca 2þ ] i that accompany HPV were also inhibited by PP2. Conclusion Hypoxia activates srcFKs and triggers protein tyrosine phosphorylation in IPA. Hypoxiamediated Rho-kinase activation, Ca 2þ sensitization, and [Ca 2þ ] i responses are depressed by srcFK inhibitors and/or siRNA knockdown, suggesting a central role of srcFKs in HPV.
Introduction
Hypoxic pulmonary vasoconstriction (HPV) is the acute localized adaptive process whereby blood flow is directed away from poorly ventilated areas of the lung in order to maximize ventilation-perfusion matching. In isolated pulmonary arteries, HPV is typically biphasic, characterized by a large but transient first phase and a sustained and often gradually developing second phase. 1, 2 The first phase is associated with a sizeable transient elevation in intracellular Ca 2þ ([Ca 2þ ] i ), whereas during the second phase, there is a relatively small and rapidly stabilizing increase in [Ca 2þ ] i , 2 the effect of which is greatly enhanced by a Rho-kinasedependent Ca 2þ sensitization pathway. 3 src-family kinases (srcFKs) are a group of closely related non-receptor tyrosine kinases, of which three (src, fyn, and yes) are highly expressed in pulmonary artery. 4 Although tyrosine kinases are essential components of cell growth and proliferation signalling, they have also been implicated in vascular smooth muscle contraction. 5, 6 We have recently shown in rat pulmonary artery, as have others in porcine coronary artery, that agonist-induced Rho-kinase-mediated Ca 2þ sensitization and force generation is dependent on srcFKs.
4,7
Ca 2þ sensitization of the contractile apparatus occurs through inhibition of myosin light-chain phosphatase (MLCP), leading to increased phosphorylation of the 20 kDa myosin light-chain (MLC 20 ) , independently of changes in [Ca 2þ ] i . 8 MLCP inhibition occurs through phosphorylation of the myosin-binding subunit MYPT-1 9 via Rho-kinase. 10 , 11 We have shown that the second phase of HPV is selectively inhibited by the Rho-kinase blocker Y27632 but not by the PKC blocker Ro31-8220. 2, 3 In addition, hypoxia enhances phosphorylation of MYPT-1 and MLC 20 in cultured pulmonary artery smooth muscle cells (PASMCs). 12, 13 Rho-kinasemediated Ca 2þ sensitization is also a key factor in the pathogenesis of chronic hypoxia-induced pulmonary hypertension. 14, 15 Two studies using broad-spectrum tyrosine kinase blockers (genistein and tyrphostin) have suggested the involvement of tyrosine kinases in HPV. 16, 17 src and fyn are both activated by hypoxia in cardiac myocytes, 18 and src plays a crucial role in hypoxia-inducible factor (HIF-1) induction in vascular smooth muscle cells. 19 However, a specific role of srcFKs in HPV and the contractile pathways affected remains to be determined. In the present study, therefore, we evaluated the role of srcFKs in HPV of rat small distal pulmonary arteries and determined how this relates to the hypoxiamediated Rho-kinase- 
Measurement of force and intracellular Ca 21
Intra-pulmonary arteries (second-to third-order; 150-400 mm diameter) were mounted on a Mulvany-Halpern wire myograph (DMT A/S, Aarhus, Denmark), bathed in PSS at 378C, pH 7.4, and stretched to give a wall tension equivalent to a transmural pressure of 30 mmHg. 1 All tension experiments were preceded by equilibration with three 3 min contractions to 80 mM K þ -substituted PSS (K þ PSS). In order to elicit a full contractile response to hypoxia, IPAs were pre-constricted with a concentration of PGF 2a necessary to produce tension equivalent to 10-15% of that produced by 80 mM K þ PSS (typically 5 mM), and then made hypoxic for 40 min. Two HPV responses were elicited in each artery; the second of which in treated arteries was preceded by a 10 min pre-incubation with inhibitor. In the presence of inhibitor, the concentration of PGF 2a required to achieve a 10-15% pre-constriction was adjusted accordingly. 20 Isolated IPAs were mounted either on a modified Cambustion AM-10 myograph (Cambustion Ltd, Cambridge, UK) or on a confocal wire myograph (Danish Myo Technology). After stretching and equilibration as described above, IPAs were incubated for 1 h at 378C in PSS containing 4 mM Fura PE-3/AM, and for a further 30 min to allow for de-esterification. Myograph modules were mounted on an inverted microscope (Nikon Diaphot, Nikon UK Ltd, Kingston-upon-Thames, UK) with a Â10 or Â20 Fluor objective combined with a double-excitation microfluorimeter (CairnResearch Ltd, Faversham, UK). Tension was recorded simultaneously with light emitted by the whole artery at .510 nm at excitation wavelengths 340 and 380 nm. The ratio of the emission intensities (R 340/380 ) was taken as a measure of [Ca 2þ ] i .
Western blot
Intra-pulmonary artery samples (half main IPA plus 2-3 second-order side-branches per sample) were subjected to a 15 min equilibration period in normoxic PSS at 378C, followed by a 10 min pre-incubation with pharmacological agents where appropriate. IPAs were then made hypoxic for 1, 2 5, 10, or 30 min and snap frozen in liquid N 2 , prior to homogenization. Protein was extracted in 50 mL of Tris-SDS sample buffer containing phosphatase and protease inhibitor cocktails (Sigma). Protein extracts (12-15 mL per lane) were run on SDS-PAGE gels (4-12% gradient, Invitrogen), transferred to nitrocellulose membrane and blocked with 5% skimmed milk for 1 h at room temperature. Membranes were probed with primary antibody overnight at 48C (1:500-1:5000 dilution where appropriate) in Trisbuffered saline containing 0.05% Tween 20 and 1% skimmed milk, followed by horseradish-peroxidase-conjugated anti-IgG secondary antibody for 1 h at room temperature (1:5000 dilution with 1% milk). Protein bands were visualized with chemiluminescence reagent (Pierce, Cramlington, UK, or Amersham, Bucks., UK) and then exposed to photographic film. Membranes were first probed with anti-phospho-antibodies, stripped for 1 h (Pierce stripping buffer), re-blocked, and re-probed with corresponding anti-total antibodies. Band intensity was expressed as a ratio of phospho/ total for each protein, and values from each treated sample were normalized to those from control (untreated) samples run on the same gel. Two to three control samples were run on each gel and averaged. Antibodies were obtained from Cell Signalling, Upstate (UK), Santa Cruz Biotechnology (CA, USA), or Sigma.
siRNA design and transfection
siRNAs were designed as described previously. 21, 22 The 19 nucleotide target sequences (src-siRNA: position 614-632, GenBank accession no. AF157016; and fyn-siRNA: position 1096-1114, GenBank accession no. U35365) were synthesized into 64-65 mer oligonucleotides with BamHI/HindIII overhangs (Eurofins MWG Operon) and cloned into the expression vector pSilencer 3.0-H1 (Ambion Inc.). All clones were purified using an EndoFree Plasmid Maxi Kit (Qiagen Ltd) and sequenced (Geneservice Ltd) (see Supplementary material online for more details).
Pulmonary artery smooth muscle cells were dispersed enzymatically and grown in DMEM with 10% FCS to passage 3 or 4. Cells were plated on 13 mm coverslips and then growth arrested for 24 h. Identification of cells as smooth muscle was verified by positive staining with anti-smooth muscle a-actin and anti-calponin antibodies (as described previously 4 ). Cells were transfected using the Basic Nucleofector w Kit for primary smooth muscle cells and a nucleofector device (Amaxa Biosystems). After 72 h, the transfection efficiency was .90%, determined using pmaxGFP (green fluorescent protein expressing vector) provided in the kit and confirmed by fluorescence microscopy. Efficiency and selectivity of knockdown was confirmed by western blot (see Supplementary material online).
Rho-kinase translocation
Pulmonary artery smooth muscle cells were treated in DMEM at 378C under either normoxic or hypoxic conditions for 40 min. Reactions were terminated by addition of paraformaldehyde fixative. Fixed cells were permeabilized with Triton-100 and stained overnight with anti-ROCK-2 primary antibody (1:100) at 48C following with incubation with Alexa Fluor 488-labelled secondary antibody (1:300) for 2 h at room temperature. Specificity of anti-ROCK-2 was confirmed by western blot (single band at 160 kDa), and staining was negative with secondary antibody alone (as described previously 4 ). 
Data analysis and statistics

Results
srcFK inhibitors block hypoxic pulmonary vasoconstriction
Hypoxic pulmonary vasoconstriction was induced by preconstricting IPA with a low concentration of PGF 2a (typically 5-10 mM) then making the chamber hypoxic for 40 min. Hypoxia induced a biphasic contractile response comprising a rapid transient phase followed by a slower sustained phase which was fully reversed upon re-oxygenation, as described previously. [1] [2] [3] Two hypoxic exposures were performed in each artery. Drugs were applied during the second exposure and their effects were compared with the second exposure in untreated time controls. In time control experiments, the second HPV response was consistently larger than the first (n ¼ 16, data not shown). HPV was inhibited by pre-incubation with the srcFK inhibitors SU6656 23 and PP2 24, 25 ( Figure 1A and B). We used concentrations of SU6656 and PP2 previously shown to be required for inhibition of srcFK auto-phosphorylation and protein tyrosine phosphorylation in IPAs. 4 The sustained phase was diminished by both Figure 1 Effects of src-family kinase (srcFK) inhibitors on hypoxic pulmonary vasoconstriction in intra-pulmonary arteries. Intra-pulmonary arteries were preconstricted with PGF 2a before being made hypoxic. Example traces (top panels) show the effects of hypoxia first in the absence (upper trace), and then in the presence (lower trace) of inhibitors. The sustained phase contraction was inhibited by the srcFK inhibitors SU6656 [(A) 3 mM, 33 + 10% block, *P , 0.05, n ¼ 8 arteries; 30 mM, 56 + 6% block, **P , 0.001, n ¼ 8 arteries] and PP2 [(B) 3 mM, 37 + 6% block, *P , 0.01, n ¼ 10 arteries; 30 mM, 64 + 9% block, **P , 0.001, n ¼ 10 arteries]. The inactive analogue PP3 also partially inhibited the sustained phase at 30 mM [(C ) 28 + 6% block, *P , 0.05, n ¼ 8 arteries], but this effect was significantly less than for PP2 ( † P , 0.01 vs. 30 mM PP2); PP3 had no effect at 3 mM. The transient phase was partially inhibited by SU6656 (30 mM, 23 + 10% block, *P , 0.01) and PP2 (30 mM, 35 + 9% block, *P , 0.01).
src and hypoxic pulmonary vasoconstriction 3 and 30 mM of each drug, whereas the transient phase was only partially blocked by 30 mM. PP3, the inactive analogue of PP2, had no effect at 3 mM and caused only a slight inhibition of the sustained phase at 30 mM ( Figure 1C Figure 2B . Hypoxia enhanced immunoreactivity at three of these bands, and this enhancement was reversed by prior incubation with 30 mM PP2 or 30 mM SU6656.
Hypoxia enhances MYPT-1 and MLC 20 phosphorylation
Since a small degree of pre-constriction is required for a full HPV response, we evaluated the effects of hypoxia on MYPT-1 and MLC 20 phosphorylation in IPAs both in the presence and absence of PGF 2a . Five micromolar PGF 2a was used throughout as this approximates the concentration required to achieve the correct level of pre-constriction. The effects of 5 mM PGF 2a itself were also evaluated. Five micromolar PGF 2a alone caused a small but sustained increase in phosphorylation at both sites ( Figure 3A and B) . As is also shown in Figure 3A , hypoxia in the presence of PGF 2a caused a large sustained enhancement of MYPT-1 phosphorylation (at thr-855, equivalent to thr-850 in human) that was substantially greater than that caused by PGF 2a alone. Hypoxia in the presence of PGF 2a also caused significant enhancement of MLC 20 phosphorylation (at ser-19, target of myosin light-chain kinase) above that of PGF 2a alone. This response was biphasic, with a peak at 5 min and another increase towards 30 min ( Figure 3B ). Hypoxia alone, however, produced a complex response in both MYPT-1 and MLC 20 phosphorylation. This was characterized by a reduction at 1 min, a small peak at 2 min, another dip at 5-10 min, and a final small increase towards 30 min, which rose significantly above control levels for both phosphorylation sites ( Figure 3C and D) .
srcFK and Rho-kinase inhibitors block hypoxia-mediated MYPT-1 and MLC 20 phosphorylation
In order to determine the contribution of Rho-kinase to phosphorylation of MYPT-1 and MLC 20 during hypoxia and the possible upstream involvement of srcFK, we performed additional 30 min exposures to hypoxia and 5 mM PGF 2a , both together and individually, with the addition of the Rho-kinase inhibitor Y27632 and the srcFK blocker SU6656. Both in the presence ( Figure 4A ) and absence ( Figure 4B ) of PGF 2a , the hypoxia-induced enhancement of phosphorylation at both sites was inhibited by both SU6656 and Y27632. The small enhancement mediated by 5 mM PGF 2a was inhibited by Y27632 at both phosphorylation sites, but only the phosphorylation of MYPT-1 was significantly reduced by SU6656 ( Figure 4C) . We have previously shown that basal phosphorylation of MYPT-1 at thr-855 and of MLC 20 at ser-19 is unaffected by SU6656 but that basal MYPT-1 phosphorylation at thr-855 is almost abolished by Y27632. 4 Inhibition of MYPT-1 phosphorylation at thr-855 by SU6656, therefore, suggests that srcFK may be regulating the activity of Rho-kinase.
Hypoxia triggers srcFK-dependent translocation of Rho-kinase in pulmonary artery smooth muscle cells
In order to confirm that srcFKs were acting upstream of Rho-kinase activation, we examined hypoxia-mediated translocation of Rho-kinase (ROCK-2) in PASMCs transfected with siRNAs directed against src, fyn, and a combination thereof, compared with sham-transfected cells. Basally, ROCK-2 was localized to the nucleus, and this was unaffected by either siRNA. Upon exposure to hypoxia, ROCK-2 translocated to the cytosol and/or cytoskeleton ( Figure 5A and D) . In cells transfected with src-siRNA and fyn-siRNA, however, translocation was completely and partially prevented, respectively ( Figure 5B-D) . Double transfection with both src-and fynsiRNAs also abolished translocation ( Figure 5D ). In the presence of PGF 2a , hypoxia greatly enhanced phosphorylation (**P , 0.001 vs. control, n ¼ 17 rats for both sites), and this enhancement was reversed by SU6656 ( † P , 0.01, n ¼ 10 rats for both sites) and Y27632 ( † † P , 0.001, n ¼ 6 rats for both sites). (B) In the absence of PGF 2a , a smaller but still significant increase was apparent (*P , 0.01, n ¼ 17 rats for both sites), and this increase too was inhibited by SU6656 ( † P , 0.01, n ¼ 10 rats for both sites) and Y27632 ( † † P , 0.001, n ¼ 6 rats for both sites). (C ) Five micromolar PGF 2a also enhanced phosphorylation (*P , 0.01, n ¼ 13 rats for both sites). This increase was significantly reduced by both SU6656 [ † P , 0.01 (MYPT-1 only), n ¼ 9 rats for both sites] and Y27632 ( † † P , 0.001, n ¼ 6 rats for both sites).
Hypoxia-induced [Ca
] i response is PP2 sensitive
In addition to Ca 2þ sensitization pathways, a rise in [Ca 2þ ] i is almost certainly also essential for a full HPV response. 20 In order to determine whether srcFKs are also involved in changes in [Ca 2þ ] i during hypoxia, we examined the effects of the srcFK inhibitor PP2 in Fura-PE3-loaded IPA. As shown in Figure 6 , hypoxia induced a biphasic [Ca 2þ ] i response, comprising a large rapid transient phase followed by a small sustained phase, superimposed on the smaller PGF 2a -mediated response. PP2 suppressed both the transient and sustained phases of this response. These experiments were not repeated with the other srcFK blocker SU6656 because of the overlap of this drug's yellow colour with the emission spectra of Fura-PE3.
Discussion
This study provides the first direct evidence for a role or roles of srcFKs in HPV and firm supportive evidence for the importance of Ca 2þ sensitization in the sustained phase of the contraction. Our observations also forge a clear link between the actions of Y27632 on hypoxic force generation 3,12 and on hypoxia-mediated enhancement of Rho-kinase-dependent MYPT-1 and MLC 20 phosphorylation. Our findings that hypoxia both activates srcFK and enhances PP2-sensitive tyrosine phosphorylation of multiple protein targets, coupled with the inhibition of HPV by both SU6656 and PP2, are suggestive of an active role of these kinases in HPV. Hypoxia has been previously shown to activate src and the closely related kinase fyn in cardiac myocytes, 18 and to enhance srcFKspecific tyrosine phosphorylation and activation of focal adhesion kinases p125 FAK and paxillin. 27, 28 p125 FAK may be the 120 kDa protein whose tyrosine phosphorylation was enhanced by hypoxia and inhibited by PP2 in the present study. HPV is believed to involve a change in the generation of reactive oxygen species (ROS) in the mitochondria. 29, 30 Many protein kinases, including srcFK, are activated by ROS, 31, 32 indeed src appears to play an essential role in many of the intracellular pathways activated by hypoxia and ROS in the systemic vasculature. 19 Exactly how srcFK activity may be induced by ROS, assuming ROS production is enhanced during hypoxia in IPAs, remains to be determined.
The time course of the phosphorylation responses to hypoxia was complex. In the absence of PGF 2a , hypoxia caused a multi-phasic phosphorylation response ending in sustained enhancement at the maximum time point of 30 min. The initial drop at 1 min was large enough to become significant with regards to MLC 20 at ser-19. A src and hypoxic pulmonary vasoconstriction similar drop (although not significant) was also apparent with MLC 20 in the presence of PGF 2a , and indeed, in isolated IPAs, we sometimes observe a small very transient relaxation immediately after inducing hypoxia that precedes the firstphase contraction (unpublished observations). The causes of these fluctuations are unknown. In the presence of PGF 2a , hypoxia caused a large sustained increase in MYPT-1 phosphorylation. This, however, was not exactly mirrored by MLC 20 phosphorylation, the time course of which resembled the time course of contraction, with a distinct transient first phase at 5 min followed by a sustained phase of up to 30 min. This is not surprising since the first phase of HPV is clearly associated with a large transient increase in [Ca 2þ ] i , whereas the sustained phase of HPV is primarily associated with a Ca 2þ sensitization pathway, as shown previously. 2, 3, 20 Prostanoids cause vascular smooth muscle contraction in part via Rho-kinase-mediated phosphorylation of MYPT-1. 33 In addition, we have recently demonstrated a direct involvement of srcFK in PGF 2a -mediated Ca 2þ sensitization and contraction in rat IPAs, in which we showed that srcFKs were activated by PGF 2a and provided evidence that srcFKs were upstream mediators of Rho-kinase translocation, and phosphorylation of MYPT-1 and MLC 20 . 4 Similarly, in this study, Rho-kinase-mediated MYPT-1 phosphorylation was inhibited by SU6656, and hypoxia-induced translocation of Rho-kinase in PASMCs was completely prevented by siRNA knockdown of src and strongly inhibited by knockdown of fyn. Therefore, srcFKs are clearly involved in the upstream regulation of hypoxia-mediated Rho-kinase activity.
Since both hypoxia and PGF 2a 4 activate srcFKs and enhance MYPT-1 and MLC 20 phosphorylation, we confirmed that the action of hypoxia on this phosphorylation or of srcFK blockers on HPV was independent of any action on the underlying pre-constriction. Hypoxia caused enhancement of Rhokinase-mediated phosphorylation of MYPT-1 in the absence as well in the presence of PGF 2a , and this enhancement was sensitive to an inhibitor of srcFKs ( Figure 4B) . However, the relative effectiveness of hypoxia in the presence of PGF 2a at enhancing phosphorylation (MYPT-1 at 30 min: 94%; and MLC 20 at 30 min: 70%) was apparently greater than the sum of the individual effects of hypoxia alone and PGF 2a alone (MYPT-1 at 30 min: 28 þ 29 ¼ 57%; and MLC 20 at 30 min: 21 þ 25 ¼ 46%), suggesting a synergistic action of the two stimuli. This is mirrored by force generation, where hypoxia in the absence of pre-constriction produced very small contractions of only 3-4% the size of that caused by 80 mM K þ PSS, 1 and yet in the presence of 5 mM PGF 2a which produces contractions of 10-15% of K þ PSS, hypoxia caused additional sustained contractions of up to 30% of K þ PSS. Thus, stimulation of srcFKs by both PGF 2a and hypoxia may explain at least part of the enhancement of HPV seen in the presence of this agonist.
In addition to an involvement in Ca 2þ sensitization, we have also found that the srcFK inhibitor PP2 blocks the hypoxia-mediated [ influx and partly due to capacitative Ca 2þ -influx triggered by release from thapsigargin-sensitive stores, whereas the sustained component is probably due to influx through another as yet uncharacterized voltage-independent pathway. 20 Other studies propound the importance of influx through voltage-gated Ca 2þ channels. 37, 38 In any case, srcFKs have been implicated in both voltage- ] i in intra-pulmonary arteries (IPAs). Example traces (upper panel) of the ratio of light emitted at .510 nm from excitation at 340 nm over that at 380 nm (R 340/380 ) against time, and average effects with time (lower panel): 30 mM PP2 inhibited both the first phase (taken at 5 min; 58 + 6% block, *P , 0.01 vs. control, n ¼ 7 arteries) and the second phase (taken at 40 min; 43 + 7% block, *P , 0.01 vs. control, n ¼ 7 arteries). Note: the level of [Ca 2þ ] i immediately before IPAs were made hypoxic was set to zero in order to distinguish the effect of PP2 on the underlying PGF 2a -induced response from that of hypoxia per se. dependent and -independent mechanisms of Ca 2þ mobilization as triggered by either agonists or ROS. 39, 40 In summary, our results suggest a direct role of srcFKs in the acute contractile response to hypoxia in small pulmonary arteries of rat. Since srcFK inhibitors block both hypoxiamediated Rho-kinase-dependent MYPT-1 phosphorylation and the hypoxic [Ca 2þ ] i response in IPAs, we may speculate that srcFKs may act upstream of both key pathways to MLC 20 phosphorylation and contraction. The specific phosphorylation targets of srcFKs as activated by hypoxia, whether they be guanine exchange factors 41 or guanine dissociation inhibitors 42 leading to RhoA/Rho-kinase activation, or L-type Ca 2þ channels 40 or phospholipase-Cg, 43 resulting in [Ca 2þ ] i mobilization, remain to be determined.
